<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903838</url>
  </required_header>
  <id_info>
    <org_study_id>S308.2.008</org_study_id>
    <secondary_id>2008-000400-81</secondary_id>
    <nct_id>NCT00903838</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study
      of pardoprunox as adjunctive treatment to levodopa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 44 patients are to be randomized in a 3:1 ratio to two possible treatment
      groups, pardoprunox and pramipexole, respectively. The first part of the study will be
      blinded and consists of a minimum 1-week screening period, a 4-week switch and stabilization
      period and an 8-week maintenance period. The second part of the study will be open label
      pardoprunox treatment with a dose adjustment period of 4 weeks followed by long term
      maintenance treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated on 31 May, 2011, due to strategic considerations.
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to endpoint in ON-time without dyskinesia</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ON-time with (troublesome) dyskinesia; OFF-time; UDysRS, UPDRS (part II + III during ON and OFF state) and Part 4</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Advanced Stage Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pardoprunox</intervention_name>
    <description>1.5 to 12 mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
    <description>0.75-4.5 mg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients who have signed informed consent

          -  Diagnosis of idiopathic Parkinson's Disease

          -  Stable treatment with L-dopa and dopamine agonist for at least 28 days prior to
             randomization

          -  Presence of a recognizable ON and OFF state (motor fluctuations)

          -  Minimum hours of OFF-time per day of 1.5 hours (during waking hours including early
             morning akinesia) as recorded per baseline diaries

          -  Minimum hours of ON time with troublesome dyskinesia of 2 hours (during waking hours)
             as recorded per baseline diaries

          -  Prevalent expression of severely disabling dyskinesias during the waking day, i.e.
             dyskinesias are present at least 25% of the waking hours (UPDRS Part 4 item 32 &gt;= 2)
             in combination with a degree of disability which is moderate or higher (UPDRS Part 4
             item 33 &gt;=2)

        Exclusion Criteria

          -  Diagnosis is unclear or a suspicion of other parkinsonian syndromes

          -  Patients who have undergone surgery for the treatment of PD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana Bronzova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Healthcare Products B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45433</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45428</name>
      <address>
        <city>Kassel</city>
        <zip>34128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45422</name>
      <address>
        <city>Tuebingen</city>
        <zip>BW 72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45427</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45435</name>
      <address>
        <city>Cassino</city>
        <zip>03043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45436</name>
      <address>
        <city>Chieti Scalo</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45437</name>
      <address>
        <city>Rome</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45438</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45439</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>August 25, 2011</last_update_submitted>
  <last_update_submitted_qc>August 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

